MT-I (Melanotan I)

MT-I (Melanotan I) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that has been studied for its ability to influence skin pigmentation.

While there has been interest in MT-I for cosmetic tanning and photoprotection concepts, its regulatory status and approved uses differ across regions, and many commercial preparations fall outside standard drug pathways.

MT-I activates melanocortin receptors involved in melanogenesis. High-level effects include:

• Stimulating melanin production in the skin
• Potentially affecting related melanocortin pathways with broader physiologic roles

The clinical significance of these actions, particularly for long-term photoprotection or other outcomes, continues to be explored.

MT-I has been investigated in selected medical and photoprotection contexts, but its role in clinical practice is limited and region-dependent. Many references to MT-I occur in cosmetic or lifestyle discussions rather than evidence-based guidelines.

Any consideration of MT-I should be framed around local regulations and current data, and should distinguish between research and cosmetic marketing claims.

Reported effects include nausea, flushing, and changes in existing pigmented lesions. Long-term consequences, including potential interactions with skin cancer risk, are not fully understood.

Dermatologic surveillance and consultation with qualified clinicians are important considerations when evaluating products that alter pigmentation.

MT-I (Afamelanotide) is less potent than MT-II but has a more favorable side effect profile.

This information summarizes commonly discussed research and clinical practices.

Formulation is what separates the approved drug from the gray-market product, and the difference is larger than the shared molecule suggests:

• Scenesse (afamelanotide) — a solid, bioresorbable sterile rod about 1.7 cm long containing 16 mg, implanted subcutaneously by a healthcare professional every 2 months, releasing peptide gradually (DailyMed).

• "MT-1" research vials — lyophilized powder for reconstitution and subcutaneous injection, with unverified content and no published pharmacokinetics in that form.

Vendors also sell Melanotan I alongside melanotan-II and market blends of the two. That pairing defeats the reason Melanotan I is the more selective compound: adding a non-selective melanocortin agonist reintroduces the appetite, cardiovascular and sexual-arousal effects that MC1-selectivity avoids. No combination of the two has been studied.

Research on MT-I has investigated its potential to modify pigmentation and photoprotection endpoints. Study designs and populations vary, and long-term outcome data are limited.

Interpretation of this literature requires attention to evolving dermatologic standards and risk–benefit considerations.

For deeper dives on this peptide, see:

• MT-I (Melanotan I) benefits and areas of interest
• MT-I (Melanotan I) side effects and safety context
• MT-I (Melanotan I) dosing concepts (educational)
• MT-I (Melanotan I) research and evidence overview

Is Melanotan I FDA approved? The molecule is — as afamelanotide, approved 8 October 2019 under NDA 210797 as Scenesse, a 16 mg subcutaneous implant, with priority review and orphan designation (Drugs@FDA). The approval covers that manufactured implant for one rare disease. Vials sold online as "MT-1" are not the approved product and carry none of its verification.

What is Scenesse actually approved for? To increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria — a rare inherited disorder in which sunlight causes burning pain. In the pivotal trials (74 EU and 94 US patients), median pain-free sun exposure was 69.4 versus 40.8 hours in the US study (P=0.04) and 6.0 versus 0.8 hours in the EU study (P=0.005) (NEJM 2015). It is not approved for tanning.

How is Melanotan I different from Melanotan II? Selectivity. Melanotan I is relatively selective for the MC1 receptor on melanocytes, so its effects concentrate in the pigment system. Melanotan-II activates melanocortin receptors broadly, adding appetite suppression, nausea, and sexual-arousal effects — the latter being what led to the development of bremelanotide (PT-141).

Does it protect against skin cancer? No trial has tested that, and increased pigmentation is not established as protection. The Scenesse label goes the other way: it warns of generalised increased pigmentation and darkening of pre-existing naevi and freckles, lists melanocytic naevus among adverse reactions at 4%, and directs that patients receive a full-body skin examination twice yearly (DailyMed).

What are the most common side effects? On the approved implant: implant site reaction (21%), nausea (19%), oropharyngeal pain (7%), cough (6%), fatigue (6%), skin hyperpigmentation (4%), dizziness (4%), and melanocytic naevus (4%). In the pivotal trials adverse events were mostly mild (NEJM 2015). A 2017 dermatology review found the unregulated versions a different story, documenting mole changes, dysplastic naevi, and four case reports of melanoma arising from existing moles during or shortly after melanotan use, without established causation (Habbema et al. 2017).